Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...

A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast ...

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert ...

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

Extensive-stage (stage IV) SCLC, on the other hand, is a disease that has spread outside the bounds of 1 radiation field, and ...

After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression ...

Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...

The FDA approved zolbetuximab-clzb (Vuloy) plus fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with locally advanced unresectable or metastatic HER2-negative ...

Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer. The FDA approved inavolisib ...